Question 1

What does the FDA-approved label specify for tirzepatide?

Accepted Answer

The FDA-approved label specifies three strengths, given once a week by injection under the skin. A 2025 review in Expert Opinion on Pharmacotherapy states that tirzepatide is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes and chronic weight management. The earlier of the two approvals is on record as well. A 2022 systematic review notes that the Food and Drug Administration approved tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise, to achieve better glycemic blood levels in patients with diabetes. Glycemic means relating to blood sugar. Two things there are worth separating. The strengths are the same for both approved uses, and the two approvals were granted separately. We report this for the same reason we report that a compound is not approved for anything. It is a statement of what a regulator decided.

Question 2

What is actually on a tirzepatide dosing chart?

Accepted Answer

Most charts circulating online are a ladder of weekly amounts with dates beside them, presented as though one sequence applied to everybody. What the published record supports is considerably narrower, and it arrives in two separate pieces that are easily confused with one another. The first piece is the approved set: 5, 10 and 15 mg once weekly. The second is what the trials did to get people there. SURMOUNT-1 assigned participants to 5 mg, 10 mg or 15 mg for 72 weeks, including a 20-week dose-escalation period. In the SURPASS-5 trial, tirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved. A chart carrying those numbers is reporting an approval alongside a trial protocol, which are two different kinds of statement about two different things. A chart that continues past them, into amounts nobody filed with a regulator or administered in a registered trial, is reporting nothing whatsoever.

Question 3

What was the starting amount in the trials?

Accepted Answer

Nobody in the published programme began at the amount they finished on. The clearest statement comes from a 2022 trial that added tirzepatide to insulin glargine in 475 adults with type 2 diabetes. In that trial, patients were randomized to receive once-weekly subcutaneous injections of 5-mg, 10-mg or 15-mg tirzepatide or placebo over 40 weeks. Tirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved. The obesity trial describes the same idea without the arithmetic. Its 72 weeks included a 20-week dose-escalation period, which is how an assignment of 15 mg is reached gradually rather than on day one. Both of those are trial protocols rather than instructions. They describe how investigators moved supervised participants toward a randomly assigned target. The material had a known identity and a known strength, and a clinic was watching. Neither is a schedule being handed to anybody holding a vial.

Question 4

What is the approved amount for weight loss?

Accepted Answer

The same three. A 2025 review states that tirzepatide is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes and chronic weight management, and a 2023 JAMA review lists it among six medicines approved by the US Food and Drug Administration for long-term use in obesity. What those strengths produced in the obesity trial was a gradient rather than a threshold. At week 72 the mean percentage change in weight stood at -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, compared with -3.1% with placebo. Read the gradient rather than only the top of it, because the distances between the steps are unequal in a way the headline figure conceals. The difference between the 10 mg and the 15 mg assignments is roughly a point and a half, while the difference between placebo and the 5 mg assignment is close to twelve percentage points. More produced more in that trial, though not proportionally more, and the investigation was never designed to identify a suitable amount for any particular individual.

Question 5

How often was tirzepatide given, and by what route?

Accepted Answer

Once a week, injected under the skin, in every published trial without exception. SURMOUNT-1 assigned participants to once-weekly, subcutaneous tirzepatide for 72 weeks. The 2025 heart failure trial gave up to 15 mg subcutaneously once per week for at least 52 weeks. The approval itself covers tirzepatide subcutaneous injections. No trial among the research behind this page has tested a different frequency, split a weekly amount across two days, or compared one injection site against another. Those are not questions the literature has answered badly; they are questions none of the sources covered here put to it, which is an absence of investigation rather than an absence of effect. Compounded vials in the FDA enforcement record carry comparable wording on their labels. A 2025 recall listing describes a 3mL Multidose Vial, For Subcutaneous Use, Rx Only, at 27 mg per 3 mL. Route is the single parameter staying consistent across the approved injection, the registered trials and the compounded supply, which makes it the only one a reader can accept without further checking.

Question 6

Is there a dosing chart for compounded tirzepatide?

Accepted Answer

No, and why not is the central point of this page. The approved schedule belongs to the approved product, which is made by a named manufacturer to a specification filed with the regulator. A compounded or research-grade vial is not that product. It carries no FDA-approved label, and nothing in the approved schedule has been established as applying to what is inside it. The recall record shows why this distinction is practical rather than legalistic. Compounded tirzepatide appears in FDA listings at 10 mg/mL, at 20 mg/mL in the same recall, at 30 mg/mL in a pre-filled syringe, at 9 mg/mL in a multidose vial, and as 60 mg in a 10 mL freeze-dried vial. Those are four different concentrations across five listings. An amount expressed in milligrams therefore establishes nothing about the volume of liquid it corresponds to until you determine which concentration you are actually holding, and no source among the research behind this page connects a particular concentration to a particular seller.

Question 7

What is the starting dose of compounded tirzepatide?

Accepted Answer

None of the research behind this page answers it, and saying so honestly is worth more than a number. No regulator has approved a compounded tirzepatide vial, so no approved label states a starting amount for one. No trial among the research behind this page has given compounded tirzepatide to anyone and reported what happened. What exists is the escalation used for the approved molecule in a registered trial: initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved. Read that carefully. It describes supervised participants, a known concentration, a verified identity and a clinic that could stop. A compounded vial shares the chemical name and none of the rest. We do not publish the step across from one to the other, because that step is the thing no study we could find has validated.

Question 8

What does microdosing tirzepatide mean?

Accepted Answer

It means using amounts below the ones that were studied, and no trial among the research behind this page has tested that. The smallest arm anywhere in the published record is 1 mg, in a 2021 analysis of 316 subjects with type 2 diabetes who received tirzepatide at 1, 5, 10 or 15 mg, dulaglutide at 1.5 mg, or placebo. That arm is informative in a narrow way. In those patients, tirzepatide 10 and 15 mg significantly decreased fasting insulin, while 1 mg sat at the bottom of the range as a comparison point rather than as a working amount. So a microdosing chart is not a scaled-down trial protocol. It is a set of amounts outside the range anyone measured, with no published result attached to any of them, and a chart cannot supply one.

Question 9

How long did people stay on these amounts?

Accepted Answer

Longer than in most trials of anything. SURMOUNT-1 ran 72 weeks, and the participants in it who had both obesity and prediabetes received their assigned dose for a total of 176 weeks, followed by a 17-week off-treatment period. Other trials across the programme ran considerably shorter. A randomised trial in Chinese adults ran 52 weeks, the sleep apnoea trials ran 52 weeks, and the heart failure trial ran at least 52 weeks, with a median duration of follow-up of 104 weeks. Nothing among the research behind this page extends past those 176 weeks of continuous administration. Duration beyond that point is unstudied rather than reassuring, and the difference between those two descriptions is the whole of what we can honestly say. The same applies to cycling, interruptions and tapering schedules, none of which any published trial has examined, so no interval exists to report.

Question 10

Why do the published amounts vary?

Accepted Answer

Because the trials were asking different questions. The diabetes programme used all three strengths to test glucose control, and a 2021 head-to-head trial assigned 1,879 patients to tirzepatide at 5 mg, 10 mg or 15 mg or to semaglutide at 1 mg. Several later investigations dropped the 5 mg arm altogether and worked instead with whichever of 10 mg or 15 mg a participant could tolerate. The sleep apnoea trials did that, the maintenance trial used 10 or 15 mg in its open-label lead-in, and the heart failure trial went up to 15 mg. So the range narrows as the research question moves from blood sugar control toward weight management. That narrowing is a design decision about where an effect was anticipated, rather than evidence that one particular amount is appropriate for one particular person.

Question 11

What does the approval not cover?

Accepted Answer

Three things, and they are the ones most often blurred together. An approval for type 2 diabetes is not an approval for weight loss. Those were granted separately, and the obesity approval appears in a 2023 JAMA review as its own entry beside five other medicines. An approval is also not a statement about a different vial containing the same molecule. It covers tirzepatide subcutaneous injections made to a filed specification, which is not a compounded syringe and not a research chemical listing. And it is not a statement about everything done with an approved vial. A 2024 cohort study describes adults receiving tirzepatide or semaglutide in formulations labeled for T2D, on or off label, which describes real prescribing rather than what a regulator cleared.

Question 12

How much weight comes off in three months?

Accepted Answer

No trial among the research behind this page of tirzepatide reports a three-month weight figure on its own. The randomised trials report at 52, 72 and 176 weeks, so a three-month number has to be pulled out of a comparison instead. The comparison that exists is a 2024 cohort study using electronic health record data from US health systems, covering 41,222 adults of whom 18,386 remained after matching. On-treatment weight change was larger for patients receiving tirzepatide at 3 months, by a difference of -2.4% against semaglutide, widening to -6.9% at 12 months. Read what that figure is. It is a gap between two groups, not an amount of weight that anybody lost, and it comes from routine care records rather than a randomised comparison. The three-month number people are looking for has not been published.

Question 13

Does the amount change what people experience?

Accepted Answer

Discontinuation rose with the amount in at least one trial. In the 2022 insulin add-on trial, treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg group, 18% in the 15-mg group and 3% in the placebo group. A 2024 JAMA review of obesity medicines gives class-level figures instead: adverse effects of these include nausea in 28% to 44% of patients, diarrhoea in 21% to 30%, and constipation in 11% to 24%. Those are not broken out by amount. So the dose-response relationship runs in two directions simultaneously, and one of those directions is the reason participants abandon a trial. The documented adverse effects, the populations excluded from these investigations, and what remains unknown about the long record are set out on the safety page.

Tirzepatide protocols in the published literature